OPKO Slips To Loss In Q3 On Impact Of Discontinued Operations, Revenue Up

OPKO Health reported a Q3 net loss of $53.5M, or $0.07 per share, compared to a profit of $21.6M a year earlier. Revenue from continuing operations rose 16% to $65.4M. The company agreed to sell remaining BioReference operations to Labcorp for up to $872M. OPKO also issued $125M in senior secured royalty notes and provided updates on several clinical trials. Full-year 2026 revenue is expected between $268M and $278M.

Original reporting
Published Nov 16, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$OPK
Bullish
high confidence
Mentioned
$OPK
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$OPKBullishHigh
01

Why it matters

The transaction is expected to strengthen OPKO's cash position and reduce ongoing losses, likely supporting the share price.

02

Market read

A material cash deal for a micro‑cap biotech provides a clear trading catalyst, with potential upside for OPKO shares.

03

What to watch

Contingent payments tied to Labcorp's 4Kscore test sales introduce uncertainty on total proceeds.

Relevance 8/10Novelty 8/10Timing: today

Background

OPKO Health reported Q3 loss and disclosed a major divestiture of its BioReference diagnostic business to Labcorp for $722 million, with up to $150 million in contingent payments.

Company-level read

Ticker impact

$OPKBullishHigh confidence
Context

OPKO announced a $722 million cash sale of its BioReference diagnostic operations to Labcorp, a new transaction not previously disclosed.

Expected impact

likely upside as investors price in the cash proceeds and reduced loss exposure

Evidence & confidence

A sizable cash acquisition of a discontinued business is a material catalyst for a micro‑cap biotech; the market typically reacts positively to such cash‑generating deals.

Market effects

Consolidation in the diagnostic services market may pressure peers, but OPKO's cash proceeds could set a benchmark for similar divestitures.

US biotech micro‑caps may see modest buying interest as cash‑rich deals emerge.

Limited to the niche diagnostic and biotech sector.

Counterpoint

The sale removes a revenue source; if integration risks for Labcorp materialize, OPKO could face future earnings volatility.

Key entities

  • OPKO Health, Inc.

    US‑listed biotech (ticker OPK) selling BioReference diagnostics.

  • Labcorp

    Buyer of BioReference assets.

Related articles

$HNGEMed

The Zacks Analyst Blog Highlights Hinge Health, OPKO Health, Globus Medical and Merit Medical Systems

Hinge Health (HNGE) stock surged 146.3% YTD, outperforming the industry and S&P 500. Q3 revenue grew 52% YoY to $235M, with operating margin expanding to 33%. The company raised 2026 revenue guidance to $879-$881M. Growth is driven by member engagement, AI efficiencies, and expansion into migraine and GI care. Risks include execution challenges in new care categories. Zacks ranks HNGE as Strong Buy.

$OPKMed

What OPKO Health (OPK) Said on Its Q3 Earnings Call

OPKO Health reported Q3 revenue of $65.4M, up from $56.4M a year earlier, driven by product revenue and royalties. Operating loss narrowed to $31.4M. The company has $403.2M in cash and raised $125M via secured notes. OPKO repurchased 7.2M shares and may accelerate buybacks post-Labcorp deal. Clinical programs, including MDX-2001 and MDX-2004, are progressing, with data expected in 2027.

$OPKMed

OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp

OPKO Health Inc (OPK) reported Q3 2026 revenue growth of 16% YoY, driven by product revenue and strong performance from key products. The company expects to receive $722M in cash from the LabCorp transaction, plus up to $150M in royalties. OPK strengthened its balance sheet with $125M in financing and ended the quarter with $403.2M in cash. The company repurchased 7.2M shares for $10.6M.

$OPKHighAI 9/10

OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Results of Operations and Financial Condition. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial re